Abbott Competitive Intelligence & Landscape

Abbott (abbott.com) is a global healthcare leader dedicated to creating life-changing healthcare technologies to help people live healthier, fuller lives at all stages. The company's mission is centered around making revolutionary health technologies and products accessible and affordable, with a goal to improve the lives of one in every three people on the planet by 2030 [https://www.abbott.com/content/dam/corp/abbott/en-us/hub/Abbott-Overview.pdf].

Abbott specializes in a diverse range of healthcare segments including nutrition, diabetes management (e.g., Freestyle Libre, Lingo), diagnostics testing (e.g., shaping the future of cancer testing, BinaxNOW COVID-19 test), cardiovascular health, pain and movement solutions, biowearables, and medicines [https://abbott.com/]. Key products include Ensure, Similac, Glucerna, Pedialyte, and PediaSure [https://www.abbott.com/en-us/about-abbott/contact].

Founded over 135 years ago, Abbott has headquarters in north suburban Chicago [https://www.abbott.com/content/dam/corp/abbott/en-us/abbottcorpnews/pdf/Corporate-Fact-Sheet.pdf] and operates in more than 160 countries [https://www.abbott.com/content/dam/corp/abbott/en-us/abbottcorpnews/pdf/Corporate-Fact-Sheet.pdf]. As of 2024, the company reported $42 billion in sales and employs approximately 114,000 people globally [https://www.abbott.com/content/dam/corp/abbott/en-us/abbottcorpnews/pdf/Corporate-Fact-Sheet.pdf]. The company is led by Chairman and Chief Executive Officer Robert B. Ford [https://www.abbott.com/en-us/about-abbott/leadership].

Abbott (abbott.com) focuses on providing life-changing healthcare technologies across various sectors, including Nutrition, Diabetes Care, Diagnostics Testing, Cardiovascular, Pain and Movement, Biowearables, and Medicines [https://www.abbott.com/en-us/products-solutions]. The company emphasizes making advanced medical solutions accessible and affordable, a core aspect of its pricing strategy. While specific pricing tiers for all products are not publicly detailed, Abbott highlights its commitment to affordability, particularly with its FreeStyle Libre continuous glucose monitoring (CGM) technology. This system is noted for being significantly less expensive than other CGMs, enabling broader access for individuals managing diabetes [https://www.abbott.com/content/dam/corp/abbott/en-us/documents/pdfs/newsroom/FINAL-FreeStyle-Libre-Pricing-Infographic-10Feb2021.pdf].

For its biowearables, Abbott offers products like Lingo, a continuous glucose monitor that provides real-time glucose tracking and personalized insights without requiring a prescription. The FreeStyle Libre systems are also part of their biowearable offerings, specifically designed for people living with diabetes [https://www.abbott.com/en-us/products-solutions/biowearables]. The company aims to make diabetes management easier through innovative technology, including compatible insulin pumps and mobile apps that integrate with their CGM systems [https://www.abbott.com/en-us/products-solutions/diabetes]. This focus on integrated, user-friendly solutions suggests a value-based pricing approach, where the convenience and comprehensiveness of the system contribute to its overall utility for consumers.

In diagnostics testing, Abbott provides a wide range of solutions, including rapid diagnostics for cardiometabolic and infectious diseases, molecular diagnostics for women’s health, and transfusion medicine [https://www.abbott.com/en-us/products-solutions/diagnostics-testing]. Their cardiovascular portfolio includes innovative pacemaker systems, cardiac resynchronization and defibrillator technology, and insertable cardiac monitors, all designed to assist physicians in managing cardiac arrhythmias [https://www.abbott.com/en-us/products-solutions/cardiovascular]. Furthermore, Abbott addresses cancer care challenges in emerging markets by expanding access to biologic oncology treatments through strategic partnerships, indicating a focus on affordability and accessibility in these regions for life-changing therapies [https://www.abbott.com/en-us/products-solutions/medicines].

Abbott (abbott.com) is actively engaged in global hiring, focusing on building better, healthier lives and aiming to improve the lives of 3 billion people annually by 2030 [https://www.abbott.com/en-us/careers]. The company consistently recruits across diverse fields, including Digital Technology, Information Technology, Marketing, Operations, Sales, and Finance [https://www.abbott.com/en-us/careers/search-jobs].

Abbott emphasizes career development, offering opportunities for both experienced professionals and those just starting their careers, including internships, co-op programs, and apprenticeships for students and recent graduates [https://www.abbott.com/en-us/careers/faqs]. The company encourages new hires to explore various career paths and develop skills that facilitate movement between different teams [https://www.abbott.com/en-us/careers/working-with-us/reaching-your-potential/early-careers]. This approach signals a strategic focus on talent development and internal mobility to support its broad healthcare technology mission.

A notable recent development in Abbott's hiring strategy includes the integration of Exact Sciences roles, with job seekers interested in these positions continuing to apply through existing portals [https://www.abbott.com/en-us/careers/search-jobs]. This indicates a strategic expansion or consolidation within their operational scope, particularly in areas like cancer testing, as highlighted on their homepage [https://abbott.com/]. While no specific layoff information is available from the provided sources, the consistent emphasis on growth, global impact, and diverse career opportunities suggests a robust and forward-looking hiring pattern aligned with their commitment to life-changing healthcare technologies.

Abbott (abbott.com) demonstrates a strong financial performance, with full-year 2025 sales totaling $44.3 billion, reflecting a 6.7% organic increase for the underlying base business. The company also achieved adjusted diluted earnings per share (EPS) of $5.15 in 2025, marking a 10% growth. In the fourth quarter of 2025, sales reached $11.5 billion, with organic growth of 3.8% excluding COVID-19 testing-related sales, and adjusted diluted EPS grew 12% to $1.50.

Looking at quarterly results, Abbott reported worldwide sales of $10.4 billion in Q1 2025, a 6.9% increase on an organic basis, with adjusted diluted EPS of $1.09. Q2 2025 saw total company sales worldwide at $11.1 billion, representing a 7.5% organic sales growth for the underlying base business, and adjusted diluted EPS of $1.26. By Q3 2025, the company delivered strong performance with organic sales growth for the underlying base business at 7.5% and adjusted diluted EPS of $1.30, reaffirming its full-year guidance with an EPS midpoint.

Abbott actively pursues strategic acquisitions to enhance its portfolio, as evidenced by the completion of its acquisition of Exact Sciences in Q1 2026. This move strategically positions Abbott with a "new high-growth cancer diagnostics business," aligning with its commitment to "Shaping the future of cancer testing" and expanding its life-changing healthcare technologies.

Abbott (abbott.com) actively participates in and hosts various professional conferences, trade shows, and community events, demonstrating its commitment to advancing healthcare technologies and fostering collaboration. The company maintains a significant presence at major medical conferences, including EHRA, which it has attended in 2024 [https://electrophysiology.abbott.com/EHRA-2024-Home.html], 2025 [https://info.abbott.com/EHRA-2025.html], and will attend in 2026 [https://electrophysiology.abbott.com/EHRA-2026-EP.html], showcasing advancements in cardiac rhythm management, mapping, ablation, and PFA technology. Similarly, Abbott is a regular participant at TCT, with an announced presence for TCT 2025 [https://vascular.abbott.com/abbott-at-tct.html], where it provides scientific symposia, expert meetings, and highlights innovations in action. The company also attends HRS 2025 [https://structuralheart.abbott.com/hrs-laao.html], emphasizing its involvement in structural heart advancements.

Beyond cardiology, Abbott also attends and sponsors a range of other professional conferences, such as the 10th Endocrinology Congress of Serbia and the 18th BASICS Summit of Interventional Cardiology, Cardiovascular Therapy and Imaging, among others, as noted for Q1-Q2 2025 [https://www.abbott.com/content/dam/corp/abbott/en-us/documents/pdfs/transparency/Professional-conferences-sponsored-by-Abbott-Q1-Q2-2025.pdf]. Its participation extends to events like CIRSE 2022 [https://vascular.abbott.com/abbott-at-cirse.html], where it hosted scientific sessions and offered hands-on demonstrations of endovascular innovations.

Abbott also takes center stage at prominent healthcare technology events, with its Chairman and CEO delivering keynote presentations, such as at the HLTH conference, to discuss the future of healthcare and patient-empowering connected technologies like biowearables [https://www.abbott.com/en-us/corpnewsroom/strategy-and-strength/abbott-at-hlth-the-future-of-healthcare].

In addition to external conferences, Abbott hosts its own significant events. The a:care Congress, now in its third edition, is a notable example, with the 2024 event focusing on medication adherence and behavioral science [https://acarepro.abbott.com/congress-2024/], [https://acarepro.abbott.com/articles/general-topics/2024-acare-congress-medication-adherence/]. This congress brings together healthcare professionals and experts to address the challenge of non-adherence through digital health and behavioral science.

Abbott also conducts specific tutorials and educational sessions at the conferences it attends, providing opportunities for healthcare professionals to learn about its latest technologies and clinical insights, as seen with its tutorials at EHRA 2024 [https://electrophysiology.abbott.com/EHRA-2024-Home.html]. These various participations and hosted events underscore Abbott's role in scientific discourse, professional development, and community engagement within the healthcare sector.